The overall objective of thisapplication is to use next generation gene-expression and bioinformatics technology toidentify a molecular signature found in T1 cancers that can differentiate which tumors are likely to 1) respond to intravesical BCG or 2) are resistant to BCG with a high likelihood of progression.
|Effective start/end date||9/1/17 → 8/31/19|
- Hope Foundation (Agmt 8/30/17)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.